INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1901, 24942, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1902, 25793, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1903, 25794, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1904, 29025, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1905, 29026, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1906, 29417, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1907, 32142, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1908, 353, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1909, 534, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1910, 537, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1911, 593, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1912, 695, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1913, 696, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1914, 8507, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1915, 8508, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1916, 9016, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1917, 9017, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1918, 12101, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1919, 12626, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1920, 12628, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1921, 13749, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1922, 13962, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1923, 13974, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1924, 15854, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1925, 16807, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1926, 17565, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1927, 17700, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1928, 23747, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1929, 24942, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1930, 25793, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1931, 25794, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1932, 29025, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1933, 29026, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1934, 29417, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1935, 32142, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1936, 7612, 'Leuprolide', 'Cardiovascular Diseases', 'Increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported in association with the use of GnRH agonists such as leuprolide, and triptorelin.  Cardiovascular risk factors should be evaluated carefully before treatment initiation.  Patients should be monitored for symptoms and signs suggestive of development or cardiovascular disease and should be managed according to current clinical practice.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1937, 22101, 'Leuprolide', 'Cardiovascular Diseases', 'Increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported in association with the use of GnRH agonists such as leuprolide, and triptorelin.  Cardiovascular risk factors should be evaluated carefully before treatment initiation.  Patients should be monitored for symptoms and signs suggestive of development or cardiovascular disease and should be managed according to current clinical practice.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1938, 22125, 'Leuprolide', 'Cardiovascular Diseases', 'Increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported in association with the use of GnRH agonists such as leuprolide, and triptorelin.  Cardiovascular risk factors should be evaluated carefully before treatment initiation.  Patients should be monitored for symptoms and signs suggestive of development or cardiovascular disease and should be managed according to current clinical practice.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1939, 22126, 'Leuprolide', 'Cardiovascular Diseases', 'Increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported in association with the use of GnRH agonists such as leuprolide, and triptorelin.  Cardiovascular risk factors should be evaluated carefully before treatment initiation.  Patients should be monitored for symptoms and signs suggestive of development or cardiovascular disease and should be managed according to current clinical practice.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1940, 7612, 'Leuprolide', 'Diabetes Mellitus', 'Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists such as leuprolide and triptorelin.  Caution is advised in patients with diabetes as treatment with these agents may risk glycemic control.  Monitor blood glucose and/or HbA1c periodically in patients receiving treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1941, 22101, 'Leuprolide', 'Diabetes Mellitus', 'Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists such as leuprolide and triptorelin.  Caution is advised in patients with diabetes as treatment with these agents may risk glycemic control.  Monitor blood glucose and/or HbA1c periodically in patients receiving treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1942, 22125, 'Leuprolide', 'Diabetes Mellitus', 'Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists such as leuprolide and triptorelin.  Caution is advised in patients with diabetes as treatment with these agents may risk glycemic control.  Monitor blood glucose and/or HbA1c periodically in patients receiving treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1943, 22126, 'Leuprolide', 'Diabetes Mellitus', 'Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists such as leuprolide and triptorelin.  Caution is advised in patients with diabetes as treatment with these agents may risk glycemic control.  Monitor blood glucose and/or HbA1c periodically in patients receiving treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1944, 7612, 'Leuprolide', 'Long QT Syndrome', 'Androgen deprivation therapy may prolong the QT/QTc interval.  Health care providers should consider if benefits of therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or taking other drugs that can also prolong the QT interval.  Consider periodic monitoring of EKG and electrolytes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1945, 22101, 'Leuprolide', 'Long QT Syndrome', 'Androgen deprivation therapy may prolong the QT/QTc interval.  Health care providers should consider if benefits of therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or taking other drugs that can also prolong the QT interval.  Consider periodic monitoring of EKG and electrolytes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1946, 22125, 'Leuprolide', 'Long QT Syndrome', 'Androgen deprivation therapy may prolong the QT/QTc interval.  Health care providers should consider if benefits of therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or taking other drugs that can also prolong the QT interval.  Consider periodic monitoring of EKG and electrolytes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1947, 22126, 'Leuprolide', 'Long QT Syndrome', 'Androgen deprivation therapy may prolong the QT/QTc interval.  Health care providers should consider if benefits of therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or taking other drugs that can also prolong the QT interval.  Consider periodic monitoring of EKG and electrolytes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1948, 7612, 'Leuprolide', 'Bone Diseases, Metabolic', 'Decreased bone density has been reported in men who have had orchiectomy or who have been treated with a GnRH agonist analog as leuprolide.  It can be anticipated that long periods of medical castration in men will have effects on bone density.  Bone density loss may not be reversible.  Therapy with leuprolide should be administered cautiously in patients with major risk factors for decreased bone mineral content, such as chronic alcohol and/or tobacco use, a strong family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, corticosteroids).  Therapy beyond six months with gonadotropin-releasing hormone analogs is not recommended for patients with major risk factors for decreased bone mineral content.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1949, 22101, 'Leuprolide', 'Bone Diseases, Metabolic', 'Decreased bone density has been reported in men who have had orchiectomy or who have been treated with a GnRH agonist analog as leuprolide.  It can be anticipated that long periods of medical castration in men will have effects on bone density.  Bone density loss may not be reversible.  Therapy with leuprolide should be administered cautiously in patients with major risk factors for decreased bone mineral content, such as chronic alcohol and/or tobacco use, a strong family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, corticosteroids).  Therapy beyond six months with gonadotropin-releasing hormone analogs is not recommended for patients with major risk factors for decreased bone mineral content.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1950, 22125, 'Leuprolide', 'Bone Diseases, Metabolic', 'Decreased bone density has been reported in men who have had orchiectomy or who have been treated with a GnRH agonist analog as leuprolide.  It can be anticipated that long periods of medical castration in men will have effects on bone density.  Bone density loss may not be reversible.  Therapy with leuprolide should be administered cautiously in patients with major risk factors for decreased bone mineral content, such as chronic alcohol and/or tobacco use, a strong family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, corticosteroids).  Therapy beyond six months with gonadotropin-releasing hormone analogs is not recommended for patients with major risk factors for decreased bone mineral content.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1951, 22126, 'Leuprolide', 'Bone Diseases, Metabolic', 'Decreased bone density has been reported in men who have had orchiectomy or who have been treated with a GnRH agonist analog as leuprolide.  It can be anticipated that long periods of medical castration in men will have effects on bone density.  Bone density loss may not be reversible.  Therapy with leuprolide should be administered cautiously in patients with major risk factors for decreased bone mineral content, such as chronic alcohol and/or tobacco use, a strong family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, corticosteroids).  Therapy beyond six months with gonadotropin-releasing hormone analogs is not recommended for patients with major risk factors for decreased bone mineral content.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1952, 7612, 'Leuprolide', 'Seizures', 'Convulsions have been observed in patients taking leuprolide, including patients who have a history of seizures, epilepsy, or brain disorders, and in those taking medications associated with convulsions.  Convulsions have also been reported in patients without any of these conditions.  Caution is advised in patients with a history of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1953, 22101, 'Leuprolide', 'Seizures', 'Convulsions have been observed in patients taking leuprolide, including patients who have a history of seizures, epilepsy, or brain disorders, and in those taking medications associated with convulsions.  Convulsions have also been reported in patients without any of these conditions.  Caution is advised in patients with a history of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1954, 22125, 'Leuprolide', 'Seizures', 'Convulsions have been observed in patients taking leuprolide, including patients who have a history of seizures, epilepsy, or brain disorders, and in those taking medications associated with convulsions.  Convulsions have also been reported in patients without any of these conditions.  Caution is advised in patients with a history of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1955, 22126, 'Leuprolide', 'Seizures', 'Convulsions have been observed in patients taking leuprolide, including patients who have a history of seizures, epilepsy, or brain disorders, and in those taking medications associated with convulsions.  Convulsions have also been reported in patients without any of these conditions.  Caution is advised in patients with a history of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1956, 154, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1957, 375, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1958, 400, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1959, 7207, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1960, 7242, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1961, 7243, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1962, 7261, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1963, 7270, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1964, 12654, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1965, 12655, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1966, 13769, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1967, 13786, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1968, 16227, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1969, 21090, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1970, 21717, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1971, 21735, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1972, 21754, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1973, 21756, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1974, 21767, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1975, 21768, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1976, 21769, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1977, 21836, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1978, 22609, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1979, 22881, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1980, 24258, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1981, 24259, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1982, 28607, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1983, 28608, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1984, 29825, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1985, 31862, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1986, 33460, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1987, 154, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1988, 375, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1989, 400, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1990, 7207, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1991, 7242, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1992, 7243, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1993, 7261, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1994, 7270, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1995, 12654, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1996, 12655, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1997, 13769, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1998, 13786, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1999, 16227, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2000, 21090, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '', 'DDInter', 0);
